Supernus Pharmaceuticals, Inc. (SUPN) Social Stream
SUPERNUS PHARMACEUTICALS INC (SUPN) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering SUPN.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-28 | 4 | $37 | $30 | $34 | $28.32 | 20.06% |
| 2022-01-25 | 4 | $44 | $30 | $36.5 | $28.32 | 28.88% |
| 2022-05-01 | 4 | $44 | $30 | $36 | $28.32 | 27.12% |
| 2022-08-04 | 4 | $44 | $30 | $35.5 | $28.32 | 25.35% |
| 2022-08-08 | 4 | $44 | $30 | $36.75 | $28.32 | 29.77% |
| 2022-08-31 | 4 | $44 | $30 | $38 | $28.32 | 34.18% |
| 2022-10-11 | 3 | $44 | $30 | $37.5 | $28.32 | 32.42% |
| 2022-11-29 | 3 | $43 | $33 | $38.666 | $28.32 | 36.53% |
| 2022-12-21 | 4 | $43 | $33 | $38.666 | $28.32 | 36.53% |
| 2023-01-01 | 4 | $45 | $33 | $40.25 | $28.32 | 42.13% |
| 2023-01-04 | 4 | $45 | $38 | $41.5 | $28.32 | 46.54% |
| 2023-02-28 | 4 | $47 | $38 | $43.25 | $28.32 | 52.72% |
| 2023-05-09 | 4 | $45 | $38 | $42.75 | $28.32 | 50.95% |
| 2023-05-11 | 4 | $46 | $38 | $43 | $28.32 | 51.84% |
| 2023-10-18 | 4 | $45 | $38 | $42.25 | $28.32 | 49.19% |
| 2023-10-26 | 4 | $45 | $38 | $42 | $28.32 | 48.31% |
| 2023-11-10 | 4 | $43 | $38 | $41 | $28.32 | 44.77% |
The Trend in the Analyst Price Target
SUPN's average price target has moved up $4.25 over the prior 22 months.
Over the past 42 weeks, SUPN's average upside potential has been 31.25%.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-02-28 | 4 | 47 | 38 | 43.25 | 37.59 | 15.06% |
| 2023-02-28 | 4 | 45 | 38 | 42.75 | 37.59 | 13.73% |
| 2023-04-24 | 4 | 45 | 38 | 42.75 | 37.71 | 13.37% |
| 2023-08-08 | 4 | 45 | 38 | 42.25 | 32.91 | 28.38% |
| 2023-11-10 | 4 | 43 | 38 | 41.00 | 26.65 | 53.85% |
SUPN Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.5 | 3 | 0 | 1 | 0 | 0 | 4 |
The Trend in the Broker Recommendations
Over the past 17 months, SUPN's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- SUPN has a greater number of analysts covering the stock than 275.98% of all US stocks.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, SUPERNUS PHARMACEUTICALS INC's variance in analysts' estimates is lower than -201.6% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, SUPERNUS PHARMACEUTICALS INC's upside potential (average analyst target price relative to current price) is greater than 691.57% of them.
- To contextualize these metrics, consider that out of Pharmaceutical Products stocks, SUPERNUS PHARMACEUTICALS INC's average analyst price target is greater than 1341.63% of them.
Stocks similar to SUPERNUS PHARMACEUTICALS INC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are PBH, FOLD, and CORT.
View All Top Stocks by Price Target
Make investment decisions regarding SUPN using the data that counts. Try POWR Ratings for free.